A 46-million domestic market protected by tariffs of 30–200% on over 1,000 product categories creates structured margin opportunity for manufacturers who commit to local production. Fiat opened its first Algerian plant in December 2023. Renault, Peugeot, Volkswagen, Nestlé, and Danone are already operational.
Annual Pharma Production · 2024
Algeria’s manufacturing opportunity is not primarily about cheap labour. It is about tariff structure and market access. The Algerian government has applied tariffs of between 30% and 200% on imports across more than 1,000 product categories — from finished vehicles to consumer electronics to processed food — with the explicit objective of making local manufacturing economically superior to importation. For international manufacturers evaluating their North African market access strategies, this structure creates margin that justifies the capital commitment to local production.
The automotive sector makes the case most clearly. Renault established a plant in Oran in 2014. Fiat opened its first Algerian manufacturing facility in December 2023, producing the Fiat Doblo locally. Peugeot and Volkswagen have established assembly operations. The combined effect is a functioning automotive manufacturing ecosystem with supply chain infrastructure that attracts additional entrants — the standard agglomeration dynamic that characterises every mature automotive manufacturing cluster.
The Algerian government’s “Made in Algeria” programme applies across automotive, steel, cement, electronics, pharmaceuticals, and consumer goods. Companies that achieve qualifying local content thresholds receive preferential treatment in public procurement — a significant advantage in an economy where the state remains a major buyer across most industrial categories. The programme creates a structural incentive for local manufacturing commitment beyond the tariff protection alone.
The pharmaceutical manufacturing story within the broader industrial sector is particularly significant. Algeria has built approximately 30% of Africa’s total pharmaceutical manufacturing capacity — largely without international notice. National production exceeded $4 billion in 2024. A first-in-Africa raw material production unit for anti-cancer drugs was launched in Sétif in 2024. The sector is pivoting from import substitution to sub-Saharan export ambition, creating a technology transfer and licensing window for European pharmaceutical companies that is specific, time-limited, and commercially intelligible.
Consumer market
46 million people
Import tariffs
30–200% on 1,000+ categories
Fiat plant opened
December 2023
Renault — operational
Oran — since 2014
Pharma production
$4BN+ annually
Africa pharma share
~30% of total capacity
Anti-cancer unit
World first — Sétif 2024
EU CRMA and Algerian industrial diversification programme — capital decisions being made now.
Algeria.com — operational since the late 1990s. Five partnership pathways available.